- Home
- CHN vs SGHT Comparison
CHN vs SGHT Comparison
Compare CHN & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHN
- SGHT
- Stock Information
- Founded
- CHN 1992
- SGHT 2011
- Country
- CHN United States
- SGHT United States
- Employees
- CHN N/A
- SGHT N/A
- Industry
- CHN Investment Managers
- SGHT Medical Specialities
- Sector
- CHN Finance
- SGHT Health Care
- Exchange
- CHN Nasdaq
- SGHT Nasdaq
- Market Cap
- CHN 174.6M
- SGHT 193.2M
- IPO Year
- CHN N/A
- SGHT 2021
- Fundamental
- Price
- CHN $18.19
- SGHT $5.04
- Analyst Decision
- CHN
- SGHT Buy
- Analyst Count
- CHN 0
- SGHT 8
- Target Price
- CHN N/A
- SGHT $4.50
- AVG Volume (30 Days)
- CHN 31.8K
- SGHT 222.6K
- Earning Date
- CHN 01-01-0001
- SGHT 11-06-2025
- Dividend Yield
- CHN 0.19%
- SGHT N/A
- EPS Growth
- CHN N/A
- SGHT N/A
- EPS
- CHN N/A
- SGHT N/A
- Revenue
- CHN N/A
- SGHT $76,303,000.00
- Revenue This Year
- CHN N/A
- SGHT N/A
- Revenue Next Year
- CHN N/A
- SGHT $12.04
- P/E Ratio
- CHN N/A
- SGHT N/A
- Revenue Growth
- CHN N/A
- SGHT N/A
- 52 Week Low
- CHN $9.00
- SGHT $2.03
- 52 Week High
- CHN $12.98
- SGHT $5.48
- Technical
- Relative Strength Index (RSI)
- CHN 55.16
- SGHT 69.94
- Support Level
- CHN $17.17
- SGHT $4.87
- Resistance Level
- CHN $18.31
- SGHT $5.31
- Average True Range (ATR)
- CHN 0.34
- SGHT 0.34
- MACD
- CHN -0.01
- SGHT 0.14
- Stochastic Oscillator
- CHN 71.58
- SGHT 86.89
About CHN China Fund Inc. (The)
CHINA FUND INC is a non-diversified, closed-end management investment company. Its investment objective is a long-term capital appreciation which it seeks to achieve by investing in equity securities with trading in China and outside China. It invests in various industries such as Insurance, Entertainment, Machinery, Electrical Equipment, Beverages, Hotels, Restaurants, and Leisure among others.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.